Letter: Drug interaction in resmetirom times-Reference-Cited by-同舟云学术

Letter: Drug interaction in resmetirom times

Published:2024-07-16 Issue:4 Volume:60 Page:533-534
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Zhou Xiao‐Dong¹,Liu Wen‐Yue²,Targher Giovanni³⁴^ORCID,Byrne Christopher D.⁵,Zheng Ming‐Hua⁶⁷^ORCID

Affiliation:

1. Department of Cardiovascular Medicine The Heart Center, the First Affiliated Hospital of Wenzhou Medical University Wenzhou China

2. Department of Endocrinology The First Affiliated Hospital of Wenzhou Medical University Wenzhou China

3. Department of Medicine University of Verona Verona Italy

4. Metabolic Diseases Research Unit IRCCS Sacro Cuore—Don Calabria Hospital Verona Italy

5. Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton, and University of Southampton, Southampton General Hospital Southampton UK

6. MAFLD Research Center, Department of Hepatology The First Affiliated Hospital of Wenzhou Medical University Wenzhou China

7. Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province Wenzhou China

Abstract

LINKED CONTENTThis article is linked to Harrison et al paper. To view this article, visit https://doi.org/10.1111/apt.17734

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18062

Reference7 articles.

1. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

2. Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis

3. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis